The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells

Autor: Douâa Moussa Agha, Karolien Buyl, Hassan Fahmi, Vera Rogiers, Robim Marcelino Rodrigues, Philippe Lewalle, Rahma Melki, Nathalie Meuleman, Dominique Bron, Joery De Kock, Tamara Vanhaecke, Mehdi Najar, Laurence Lagneaux, Makram Merimi
Přispěvatelé: Pharmaceutical and Pharmacological Sciences, Experimental in vitro toxicology and dermato-cosmetology, Connexin Signalling Research Group, Vriendenkring VUB
Rok vydání: 2020
Předmět:
Zdroj: Journal of Clinical Medicine, 9 (3
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 3, p 696 (2020)
Journal of Clinical Medicine; Volume 9; Issue 3; Pages: 696
ISSN: 2077-0383
DOI: 10.3390/jcm9030696
Popis: Background: As a cell‐based therapeutic, AT‐MSCs need to create an immuno‐reparativeenvironment appropriate for tissue repair. In the presence of injury, MSCs may have to proliferate and face inflammation. Clinical application requires repeated administrations of a high number of cellswith a well‐established immune profile. Methods: We have established an immuno‐comparative screening by determining the expression of 28 molecules implicated in immune regulation. This screening was performed during cell‐expansion and inflammatory priming of AT‐MSCs. Results: Our study confirms that AT‐MSCs are highly expandable and sensitive to inflammation. Both conditions have substantially modulated the expression of a panel of immunological marker. Specifically, CD34 expression was substantially decreased upon cell‐passaging. HLA‐ABC, CD40 CD54, CD106, CD274 and CD112 were significantly increased by inflammation. In vitro cell‐expansion also significantly altered the expression profile of HLA‐DR, CD40, CD62L, CD106, CD166, HLA‐G, CD200, HO‐1, CD155 and ULBP‐3. Conclusion: This study points out the response and characteristics of MSCs following expansion and inflammatory priming. It will strength our knowledge about the molecular mechanisms that may improve or hamper the therapeutic potential of MSCs. These immunological changes need to be further characterized to guarantee a safe cellular product with consistent quality and high therapeutic efficacy.
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje